Danaher Corporation (NYSE:DHR) Healthcare Conference Summary Company Overview - **Company**: Danaher Corporation - **Event**: Bank of America Securities Health Care Conference - **Date**: May 11, 2022 - **CEO**: Rainer Blair Key Points Financial Performance - Danaher reported a **12% core growth** and **8% growth** on the base business for the year - **10% EPS growth** and **$1.7 billion** in free cash flow were also highlighted as strong indicators of performance [3][4] Portfolio Repositioning - The company has undergone significant portfolio transformation, focusing on attractive end markets with strong secular growth drivers - **40%** of the portfolio is in biopharma or molecular diagnostics, with over **80%** in Life Sciences and Diagnostics - The company has **75% recurring revenues**, which is particularly strong in the current economic environment [6][4] Resilience During Economic Downturns - Danaher has demonstrated resilience during economic downturns, including the pandemic, with **25% core growth** in 2020 and **12% core growth** at the start of 2022 [7][4] M&A Activity - The company remains active in M&A, with a full pipeline of opportunities, although recent market volatility has led to a cautious approach - Danaher has previously taken advantage of market turbulence for acquisitions and is monitoring the situation closely [12][13] Bioprocessing Outlook - The bioprocessing business is expected to grow at **high single to low double-digit growth** for 2022, with a potential decline in COVID-related revenue of **$500 million to $600 million** already factored into guidance [15][17] - The development pipeline for monoclonal antibodies has increased by **50%** over the last five years, and cell and gene therapies have seen a **10x** increase [19][20] Diagnostics Segment - Beckman Coulter Diagnostics is on track for **mid-single-digit growth**, with some headwinds from COVID-related hospital restrictions in China [24] - Cepheid has doubled its installed base to over **40,000 instruments**, with a strong test menu and expected growth in non-COVID diagnostics [26][28] Market Dynamics - The transition to single-use technologies in bioprocessing is expected to drive growth, with Danaher holding the largest single-use technology business, growing over **20%** [21] - The company views home testing as complementary to point-of-care testing, enhancing overall diagnostic responsiveness [33][34] Long-term Growth Potential - Danaher anticipates mid-single-digit plus organic revenue growth, driven by a robust portfolio and attractive end markets [36] - The company has a target EBITDA margin of **35% to 40%**, with opportunities for margin expansion within the portfolio [40][42] Biotech Funding Environment - The CEO expressed confidence in the biotech funding environment, noting that the average cash runway for biotech companies is between **12 to 18 months**, which supports ongoing innovation [47] Underappreciated Aspects - Danaher has grown **50% larger** in revenue since 2019, with a significant shift in portfolio mix and an increase in recurring revenue from **45%** in 2015 to **75%** [50] Conclusion Danaher Corporation is well-positioned for continued growth, leveraging its strong portfolio in Life Sciences and Diagnostics, while navigating the challenges posed by the current economic environment and the ongoing evolution of the healthcare landscape. The company's focus on recurring revenue, M&A opportunities, and innovative technologies positions it favorably for the future.

Danaher Corporation (NYSE:DHR) Q1 2022 Earnings Conference Call April 21, 2022 8:00 AM ET Company Participants John Bedford - Vice President, Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer Conference Call Participants Derik De Bruin - Bank of America Vijay Kumar - Evercore ISI Scott Davis - Melius Research Dan Brennan - Cowen Jack Meehan - Nephron Research Patrick Donnelly - Citi Luke Sergott - Barclays Operator Good ...

Danaher Corp (NYSE:DHR) Cowen Health Care Conference Call March 8, 2022 9:10 AM ET Company Participants Rainer Blair - President, CEO & Director Matthew McGrew - CFO & EVP Conference Call Participants Daniel Brennan - Cowen and Company Daniel Brennan Good morning. Dan Brennan here from Cowen. Pleased to be here on the second day of the 42nd Annual Healthcare Conference. Joined with me on the virtual podium with the executive management team from Danaher. We have Rainer Blair, Chief Executive Officer; and Ma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-08089 DANAHER CORPORATION (Exact name of registrant as specified in its charter) Securities Reg ...

Danaher Corporation (NYSE:DHR) Q4 2021 Results Conference Call January 27, 2022 8:00 AM ET Company Participants Matthew Gugino - Vice President of Investor Relations Rainer Blair - President and Chief Executive Officer Matt McGrew - Executive Vice President and Chief Financial Officer John Bedford - Director of Investor Relations Conference Call Participants Tycho Peterson - JPMorgan Michael Ryskin - Bank of America Vijay Kumar - Evercore Scott Davis - Melius Research Dan Brennan - Cowen Jack Meehan - Nephr ...

Danaher Corporation (NYSE:DHR) JPMorgan 40th Annual Healthcare Conference Call January 11, 2022 11:15 AM ET Company Participants Rainer Blair - President and Chief Executive Officer Conference Call Participants Tycho Peterson - J.P. Morgan Tycho Peterson Morning, everybody. I'm Tycho Peterson from the life sciences team. It's my pleasure to introduce our next company this morning, Danaher. Just a quick reminder for people that have questions, you can submit questions through the Ask a Question function on t ...

Danaher Corporation Conference Call Summary Company Overview - **Company**: Danaher Corporation (NYSE:DHR) - **Date**: December 1, 2021 - **Participants**: Rainer Blair (CEO), Matt McGrew (CFO), Vijay Kumar (Evercore ISI) Key Industry Insights - **COVID-19 Testing**: Danaher's Cepheid tests can detect the Omicron variant, indicating strong product performance in the face of new variants [4][8] - **Business Impact from COVID-19**: No material impact from lockdowns in Europe has been observed on Danaher's business [6] - **Base Business Performance**: High single-digit growth is expected for the base business, supported by strong performance trends and market share gains [8][12] Financial Performance - **Q4 Guidance**: The guidance for Q4 reflects strong base business performance, with a two-year stack growth of 6-7%, which is 100 basis points higher than pre-pandemic levels [8][33] - **COVID Testing Demand**: Demand for COVID testing remains high, with expectations of shipping 16 million tests in Q4 [10][45] - **Order Book**: Danaher has a strong order book of $2 billion for vaccines and therapeutics, with 85% attributed to vaccines [19][21] Growth Drivers - **Biopharma Sector**: The biopharma segment is expected to grow at a high single-digit rate, with potential for low double-digit growth in the short term due to increased funding and market demand [16][17] - **Aldevron Acquisition**: The acquisition of Aldevron is seen as a strategic move to enhance Danaher's capabilities in genomic medicine, with expectations of over 20% growth in this segment [28][31] - **Infrastructure Investments**: The macro environment remains strong, with infrastructure improvements expected to benefit Danaher's environmental and applied solutions segment [12][34] Market Position and Strategy - **Installed Base Growth**: Danaher has nearly doubled its installed base since 2019, positioning itself as a leader in molecular diagnostics [43] - **ESG Commitment**: Danaher is focused on environmental, social, and governance (ESG) initiatives, with specific targets for diversity and sustainability metrics [55][56] - **M&A Strategy**: Danaher is actively pursuing acquisitions, with a robust pipeline of potential assets that align with its strategic goals [62] Financial Outlook - **Free Cash Flow**: Danaher aims for a free cash flow conversion ratio of around 100%, with expectations of maintaining this level in the near term [64] - **Pricing Strategy**: The company is implementing price increases of approximately 150 basis points, which is higher than historical trends, to manage inflationary pressures [41][39] Conclusion - Danaher Corporation is well-positioned for continued growth in the biopharma and diagnostics sectors, supported by strong demand for COVID testing and strategic acquisitions. The company is focused on maintaining its competitive edge through innovation, market share gains, and a commitment to ESG principles.